Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit
Exelixis (NASDAQ: EXEL) has announced its participation in the upcoming Citi 2025 Virtual Oncology Leadership Summit. The company's management will engage in a fireside chat scheduled for Wednesday, February 19 at 2:00 p.m. ET / 11:00 a.m. PT.
The presentation will be accessible via webcast on www.exelixis.com under the Investors & News section's Event Calendar page. For those unable to attend live, a replay of the session will remain available on the same platform for a minimum of 30 days following the event.
Exelixis (NASDAQ: EXEL) ha annunciato la sua partecipazione al prossimo Citi 2025 Virtual Oncology Leadership Summit. La direzione dell'azienda parteciperà a una chiacchierata informale programmata per mercoledì 19 febbraio alle 14:00 ET / 11:00 PT.
La presentazione sarà accessibile tramite webcast su www.exelixis.com nella sezione Eventi del calendario degli Investitori & News. Per coloro che non possono partecipare dal vivo, una registrazione della sessione sarà disponibile sulla stessa piattaforma per un minimo di 30 giorni dopo l'evento.
Exelixis (NASDAQ: EXEL) ha anunciado su participación en la próxima Citi 2025 Virtual Oncology Leadership Summit. La dirección de la compañía participará en una charla informal programada para miércoles 19 de febrero a las 2:00 p.m. ET / 11:00 a.m. PT.
La presentación será accesible a través de un webcast en www.exelixis.com en la página del Calendario de Eventos de la sección de Inversores y Noticias. Para aquellos que no puedan asistir en vivo, una repetición de la sesión estará disponible en la misma plataforma durante un mínimo de 30 días después del evento.
Exelixis (NASDAQ: EXEL)는 다가오는 Citi 2025 Virtual Oncology Leadership Summit에 참여할 것이라고 발표했습니다. 회사 경영진은 2월 19일 수요일 오후 2시 ET / 오전 11시 PT로 예정된 대화에 참여할 것입니다.
발표는 www.exelixis.com의 투자자 및 뉴스 섹션의 이벤트 캘린더 페이지를 통해 웹캐스트로 접근할 수 있습니다. 실시간으로 참석할 수 없는 분들을 위해, 세션의 재생은 이벤트 이후 최소 30일 동안 동일한 플랫폼에서 제공될 것입니다.
Exelixis (NASDAQ: EXEL) a annoncé sa participation au prochain Citi 2025 Virtual Oncology Leadership Summit. La direction de l'entreprise participera à une discussion informelle prévue pour mercredi 19 février à 14h00 ET / 11h00 PT.
La présentation sera accessible via un webinaire sur www.exelixis.com dans la section Événements du calendrier Investisseurs & Actualités. Pour ceux qui ne peuvent pas assister en direct, un enregistrement de la session sera disponible sur la même plateforme pendant au moins 30 jours après l'événement.
Exelixis (NASDAQ: EXEL) hat seine Teilnahme am kommenden Citi 2025 Virtual Oncology Leadership Summit angekündigt. Das Management des Unternehmens wird an einem informellen Gespräch teilnehmen, das für Mittwoch, den 19. Februar um 14:00 Uhr ET / 11:00 Uhr PT angesetzt ist.
Die Präsentation wird über einen Webcast auf www.exelixis.com unter der Rubrik Veranstaltungen im Bereich Investoren & Nachrichten zugänglich sein. Für diejenigen, die nicht live teilnehmen können, wird eine Wiederholung der Sitzung für mindestens 30 Tage nach der Veranstaltung auf derselben Plattform verfügbar sein.
- None.
- None.
-- Presentation to be webcast on www.exelixis.com --
To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. A replay will also be available at the same location for at least 30 days.
About Exelixis
Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.
Exelixis, the Exelixis logo and CABOMETYX are registered
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213810489/en/
Varant Shirvanian
Director, Investor Relations
Exelixis, Inc.
650-837-7917
vshirvanian@exelixis.com
Media Contact:
Hal Mackins
For Exelixis, Inc.
415-994-0040
hal@torchcommunications.com
Source: Exelixis, Inc.
FAQ
When is Exelixis (EXEL) presenting at the Citi 2025 Virtual Oncology Leadership Summit?
How can investors watch Exelixis's (EXEL) presentation at the Citi Oncology Summit?
How long will the replay of Exelixis's (EXEL) Citi Summit presentation be available?
What type of presentation will Exelixis (EXEL) give at the Citi 2025 Virtual Oncology Summit?
